JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

Kodu・Aktsiate loetelu・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Suletud

SektorTervishoid

42.29 -0.35

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

40.74

Max

42.66

Põhinäitajad
By Trading Economics
Sissetulek	-20M -85M
Kasumimarginaal	-867.293
Töötajad	316
EBITDA	-21M -94M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+30.71% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	3. nov 2025

Turustatistika
By TradingEconomics
Turukapital	613M 3.2B
Eelmine avamishind	42.64
Eelmine sulgemishind	42.29

Uudiste sentiment

By Acuity

67%

33%

336 / 373 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

34.81 / 38.24 Toetus ja vastupanu

Xenon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

29. okt 2025, 23:28 UTC

Kuumad aktsiad

Stocks to Watch: Chipotle, Align, Sprouts Farmers Market, Meta

29. okt 2025, 23:07 UTC

Tulu

Prudential PLC 3Q New Business Profit Up 13%

30. okt 2025, 00:00 UTC

Tulu

The Hamptons Luxury Housing Market Is Staging a Comeback for the Ages -- WSJ

30. okt 2025, 00:00 UTC

Tulu

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

30. okt 2025, 00:00 UTC

Tulu

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

29. okt 2025, 23:46 UTC

Market Talk

Nikkei May Decline Amid Caution Ahead of BOJ Decision -- Market Talk

29. okt 2025, 23:40 UTC

Tulu

Meta Shares Fall on Accelerating AI Spending Despite Record Revenue -- WSJ

29. okt 2025, 23:38 UTC

Market Talk

Gold Rises on Possible Dip-Buying After Falling on Powell's Remarks -- Market Talk

29. okt 2025, 23:25 UTC

Tulu

Alphabet Stock Jumps on Big Earnings Beat -- Barrons.com

29. okt 2025, 22:51 UTC

Tulu

Google Revenue Soars as AI Boom Lifts Cloud Business -- 2nd Update

29. okt 2025, 22:45 UTC

Tulu

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 6th Update

29. okt 2025, 22:41 UTC

Tulu

Prudential PLC 3Q New Business Profit Up 13% on Year to $705.0M >2378.HK

29. okt 2025, 22:41 UTC

Tulu

Prudential PLC APE Sales Up 10% on Year, to $1.72B >2378.HK

29. okt 2025, 22:09 UTC

Tulu

Microsoft Reports Strong Earning as Azure Cloud Revenue Soars by 40%. The Stock Is Still Down. -- Barrons.com

29. okt 2025, 22:08 UTC

Market Talk

Tulu

Starbucks Revamps Stores in Pursuit of 'Warm' Atmosphere -- Market Talk

29. okt 2025, 21:58 UTC

Tulu

Alphabet Continues to Allocate More Resources to Waymo, CFO Says

29. okt 2025, 21:58 UTC

Tulu

Alphabet's Google Cloud Backlog Rose on Strong Demand for Enterprise AI, CFO Says

29. okt 2025, 21:57 UTC

Tulu

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 5th Update

29. okt 2025, 21:54 UTC

Tulu

Meta's Margins Are Slipping As AI Costs Mount. The Stock Is Falling. -- Barrons.com

29. okt 2025, 21:46 UTC

Tulu

Alphabet CEO Sees Strong Growth and Momentum for Waymo Continuing in 2026

29. okt 2025, 21:43 UTC

Tulu

Alphabet's Google Cloud Signing Larger Deals, Deepening Relationships With Existing Customers, CEO Says

29. okt 2025, 21:43 UTC

Tulu

Alphabet CEO: More Than 70% of Existing Google Cloud Customers Use AI Products

29. okt 2025, 21:42 UTC

Tulu

IGO 1Q Nova Cash Cost A$6.84/Pound, Up 72% On-Quarter

29. okt 2025, 21:42 UTC

Tulu

IGO 1Q Nova Copper Output 1,377 Tons, Down 41% On-Quarter

29. okt 2025, 21:41 UTC

Tulu

IGO 1Q Nova Nickel Sales 3,320 Tons, Down 5% On-Quarter

29. okt 2025, 21:41 UTC

Tulu

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 4th Update

29. okt 2025, 21:41 UTC

Tulu

Alphabet Signed New Google Cloud Customers Faster in 3Q, CEO Says

29. okt 2025, 21:41 UTC

Tulu

IGO 1Q Nova Nickel Production 3,429 Tons, Down 33% On-Quarter

29. okt 2025, 21:40 UTC

Tulu

IGO: Talks Ongoing With Kwinana JV Partner to Settle on Optimum Pathway For Refinery

29. okt 2025, 21:39 UTC

Tulu

IGO 1Q Kwinana Sustaining, Improvement Capex A$8.3 Million

Võrdlus sarnastega

Hinnamuutus

Xenon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

30.71% tõus

12 kuu keskmine prognoos

Keskmine 55.59 USD 30.71%

Kõrge 65 USD

Madal 48 USD

Põhineb 15 Wall Streeti analüütiku instrumendi Xenon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

15 ratings

Osta

Hoia

Müü

Põhineb 15 analüütiku instrumendi Xenon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

34.81 / 38.24Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

336 / 373 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.